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Key Points
•Data demonstrate
comparable efficacy
between VENmono and
VEN 1 CD20 therapy
in a heavily pretreated,
high-risk CLL cohort.
Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia
(CLL) as monotherapy (VENmono) or in combination with rituximab. Whether VEN
plus anti-CD20 (VENcombo) is superior to VENmono is unknown. We conducted a
multicenter, retrospective cohort analysis comparing 321 CLL patients treated with
VENmono vs VENcombo across the United States and the United Kingdom. We examined
demographics, baseline characteristics, dosing, adverse events, response rates, and
outcomes. The primary endpoints were progression-free survival (PFS) and overall
survival (OS), estimated by Kaplan-Meier method, in patients treated with VENmono vs
VENcombo. Univariate and bivariate analyses were performed with COX regression. Three
hundred twenty-one CLL patients were included (3 median prior treatments, 78% prior
ibrutinib). The overall response rates (ORRs) were similar (VENmono, 81% ORR, 34%
complete remission [CR] vs VENcombo, 84% ORR, 32% CR). With a median follow-up of
13.4months, no differences in PFS and OSwere observed between the groups. In unadjusted
analyses, the hazard ratios (HRs) for PFS and OS for VENmono vs VENcombo were HR
1.0 (95% conﬁdence interval [CI], 0.6-1.8; P 5 .7) and HR 1.2 (95% CI, 0.6-2.3; P 5 .5),
respectively. When adjusting for differences between the cohorts, the addition of an
anti-CD20 antibody in combination with VEN did not impact PFS (HR, 1.0; 95% CI, 0.5-2.0;
P 5 .9) or OS (HR, 1.1; 95% CI, 0.4-2.6; P 5 .8). We demonstrate comparable eﬃcacy
between VENmono and VENcombo in a heavily pretreated, high-risk, retrospective cohort,
in terms of both response data and survival outcomes. Prospective studies are needed
to validate these ﬁndings.
Submitted 12 February 2019; accepted 28 March 2019. DOI 10.1182/
bloodadvances.2019000180.
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Introduction
Venetoclax (VEN) is approved as monotherapy (VENmono) or in
combination with rituximab (R) for relapsed/refractory (R/R) chronic
lymphocytic leukemia (CLL).1 Whether VEN-R (VR) is superior to
VENmono is unknown and has not been studied and is not planned to
be studied in randomized trials.2-4 Answering this question is now
more pressing in view of the accumulating recent data that fail to show
a progression-free survival (PFS) benefit to adding R or ublituximab to
ibrutinib in front-line and R/R CLL.5-8 This lack of difference contrasts
with the suggested benefit when R or ublituximab and ibrutinib were
studied in nonrandomized phase 2 studies.9,10 In the clinical trial that
led to VR approval, patients were not heavily pretreated, with very
few (2%; 8/389) exposed to ibrutinib or idelalisib. These character-
istics differ from those of patients treated with VEN in other clinical
trials or outside of studies.11 We aimed to compare response and
survival outcomes among CLL patients treated with VEN plus an
anti-CD20 monoclonal (VENcombo) antibody against patients
treated with VENmono in the R/R setting. Therefore, we conducted
a multicenter, international study examining the outcomes of 321
CLL patients treated with VEN.
Methods
We conducted a retrospective cohort study of R/R CLL patients
treated with VEN across 24 US and 42 UK academic and commu-
nity centers in partnership with the UK CLL Forum and the CLL
Collaborative Study of Real World Evidence.
To define the study cohort, investigators were asked to identify
and collect data on all CLL patients treated with VEN at their
center/practice, including those treated on clinical studies. Uti-
lizing a standardized case report form, investigators collected
data through medical chart review of CLL patients, including
demographics, disease characteristics, VEN dosing, tumor lysis
syndrome (TLS) risk and prophylaxis, and adverse events (AEs).
Detailed pre-VEN data were collected to confirm that VENmono
vs VENcombo groups represented a balanced comparison based
on potential confounders.
To understand patterns of VEN use, we collected data on its
administration as monotherapy and, if paired, which additional
agent was given. Regarding VEN dosing, we collected data on
dose reductions, dose interruptions, and duration of interruptions.
Regarding VEN combination therapy, investigators were asked if
VEN was given as (1) monotherapy or (2) paired with another agent,
and if “paired” was selected, they were then asked to select (1) R,
(2) obinutuzumab, (3) ibrutinib, or (4) other agent(s). Specific data
on “other” combinations were not collected. Patients treated with
ibrutinib and VEN were not included in this analysis. Data regarding
dose intensity and number of cycles of the paired agent were not
collected. For the planned stratified analyses, patients were cate-
gorized as VENmono or VENcombo (combination group included
patients who were treated with VEN plus either R or obinutuzumab).
TLS risk was defined according to guidance provided in the VEN
US Food and Drug Administration package insert as low, medium,
or high risk. Investigators were asked to define TLS events by
Howard criteria.12 Response rates were defined by International
Workshop on Chronic Lymphocytic Leukemia criteria as complete
remission (CR), partial remission, stable disease, and progressive
disease.13 Because of study design, response assessments and
follow-up intervals were not standardized, but time to best response
was collected. Because of the relative difficulty in identifying and
collecting a comprehensive list of AEs retrospectively, investigators
were asked to perform detailed chart reviews to accurately gather
data on select grade $3 AEs (Common Terminology Criteria for
Adverse Events criteria), including neutropenia, thrombocytopenia,
diarrhea, and febrile neutropenia. Timing, frequency, causality, and
duration of AEs were not collected.
The primary study endpoints were PFS and overall survival (OS) in
patients treated with VENmono compared with VEN plus an anti-
CD20 antibody. PFS and OS were estimated by the Kaplan-Meier
method.14 To test the association between VEN pairing status and
survival outcomes, we used COX regression to perform univariate
and bivariate analyses to compare PFS and OS for patients strat-
ified by VENmono vs VENcombo. We adjusted for potential con-
founders, including chromosome deletion 17p (del17p) status,
chromosome deletion 11q (del11q) status, Bruton tyrosine kinase
inhibitor exposure in a prior line of therapy, number of lines of prior
therapies, patient age at start of VEN, and complex karyotype
(3 or more abnormalities). For all regression analyses, hazard ratios
(HRs) with 95% confidence intervals (CIs) are reported. All other
comparisons were descriptive. Statistical analyses were performed
using STATA 10.1 (Stata Statistical Software: released 10, 2007;
StataCorp LP, College Station, TX). The study was institutional
review board approved.
Results
Baseline characteristics
A total of 321 CLL patients were included (VENmono, n 5 270;
VENcombo, n5 51). A similar proportion of patients was treated in
the context of a clinical trial in both groups (n5 7, 16% VENcombo
vs n 5 32, 12% VENmono). Baseline characteristics stratified
by VENmono vs VENcombo are included in Table 1. Patient char-
acteristics were similar except that more patients on VENmono had
complex karyotype ($3 abnormalities, P 5 .04), and VENmono
patients were more heavily pretreated (median 3 prior therapies
vs 2, P 5 .03). Both of these differences might be expected to
bias results in favor of the VENcombo group, and therefore, the
planned comparison with the study hypothesis was deemed to be
appropriate. Moreover, 89% were previously treated with a kinase
inhibitor, and 78% received prior ibrutinib (vs 2% reported in the
MURANO cohort of VEN plus R).1 The median time from most
recent therapy to starting VEN was 1.1 months.
Table 1. Baseline characteristics
Number of
patients with
available data
VEN
monotherapy
(n = 270)
VEN combination
(n 5 51; 38 R,
13 obinutuzumab)
Median age VEN start 321 68 (37-91) 66 (45-88)
Median prior therapies 321 3 (0-12) 2 (0-15)
Prior ibrutinib 319 79% 73%
Del17p 323 43% 44%
TP53 mutation 154 37% 25%
IGHV unmutated 118 83% 82%
Complex karyotype 213 43% 25%
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AEs
Available data on AEs stratified by VENmono vs VENcombo are
included in Table 2. AEs appeared to be comparable between the
VENmono and VENcombo groups. Overall, TLS risk was estimated
to be low in 38%, intermediate in 34%, and high in 28%. TLS
occurred in 9.7% of patients (9 total clinical events). The overall
discontinuation rates for VENmono vs VENcombo were similar at
41% and 39%, respectively.
Following dose escalation, 70% of patients achieved a stable VEN
dose of 400 mg daily; 33% required$1 dose interruption, and 26%
required $1 dose reduction. VEN dose interruptions ($1, 35% vs
29%) and dose reductions ($1, 28% vs 22%) were comparable
between VENmono and VENcombo groups, respectively.
Response and survival outcomes
For the entire cohort, the overall response rate (ORR) to VEN was
82% (33% CR) and was similar with VENmono (81% ORR, 34%
CR) vs VENcombo (84% ORR, 32% CR). The median time to best
response was 2.5 months for VENmono and 2.1 months for
VENcombo. With a median follow-up of 13.4 months for the entire
cohort (VENmono 13.7 vs VENcombo 12.8 months), a total of
91 progression events and 71 deaths were observed. Although the
estimated median PFS and OS were not reached, the estimated
12-month PFS and OS were 74% and 82%, respectively, for the
entire cohort. In unadjusted analyses, the HRs for PFS and OS for
VENmono vs VENcombo were HR 1.0 (95% CI, 0.6-1.8; P 5 .7)
and HR 1.2 (95%CI, 0.6-2.3; P5 .5), respectively. Figure 1 depicts
comparable PFS and OS stratified VENmono vs VENcombo in the
R/R setting.
Table 3 includes bivariate analyses of VEN pairing status (VENmono
vs VENcombo) adjusted for pre-VEN prognostic factors and their
impact on HRs for PFS and OS. When adjusting for complex
karyotype, number of prior therapies, del17p, del11q, IGHV status,
prior ibrutinib exposure, and prior chemoimmunotherapy expo-
sure, PFS and OS remained comparable between the VENmono
and VENcombo groups.
When adjusting for observed differences between the cohorts,
including both complex karyotype and the number of prior therapies,
the addition of an anti-CD20 antibody in combination with VEN did
not impact PFS (HR, 1.0; 95% CI, 0.5-2.0; P5 .9) or OS (HR, 1.1;
95% CI, 0.4-2.6; P 5 .8) as compared with VENmono.
Discussion
Given the recent broadening of the approval for VEN in R/R CLL, it
is important to study whether a clinical benefit exists for VEN plus
anti-CD20 over VENmono.2-4 With both options available, clinicians
may seek guidance in the appropriate selection of these regimens.
In the absence of randomized studies, we sought to answer this
question by retrospectively analyzing data on patients treated across
various centers in the United States and the United Kingdom.
We demonstrate comparable efficacy between VENmono and VEN
plus CD20-directed therapy in a heavily pretreated, high-risk cohort,
in terms of both response data and survival outcomes. In adjusted
and unadjusted models, there were no differences in PFS and OS
between these cohorts. PFS and OS were similar between the
groups when controlling for complex karyotype, prior ibrutinib expo-
sure, and adjusting for the number of prior therapies. Our findings
were particularly surprising because we could not identify a patient
population who benefited from the addition of an anti-CD20
antibody to VEN in terms of response and survival outcomes.
Although our analysis is limited by the retrospective design,
relatively short follow-up, and small sample size in the VENcombo
group, the length of follow-up presented here is comparable to
previously published prospective data that led to the approval
of VEN.2-4,15 Longer follow-up of patients receiving VEN may be
necessary to understand the depth and durability of response as
well as the full impact of VENcombo therapy. There were important
differences in our treatment cohorts, with the VENmono group
including patients who were more heavily pretreated and more
likely to have a complex karyotype. Despite these poor prognostic
Table 2. Adverse events
Number of
patients with
available data
VEN
monotherapy,
%
VEN
combination,
% P
TLS (overall) 321 11.5 5.8 .07
Grade 3 neutropenia 233 40.4 34 .45
Grade 3 thrombocytopenia 232 30.8 23 .27
Neutropenic fever 232 8.6 2.3 .37
Grade 3 diarrhea 230 8.7 5.1 .36
Discontinuation rate 321 41 39 .77
0.00
0 5 10
Progression Free Survival
Months
15 20 25
0.25
0.50
0.75
1.00
Ven + Anti CD20 Ven monotherapy
A
Overall Survival
0.00
0 5 10
Months
15 20 25
0.25
0.50
0.75
1.00
Ven + Anti CD20 Ven monotherapy
B
Figure 1. PFS and OS. PFS (A) and OS (B) stratified by VEN monotherapy
(VENmono) and VEN plus anti-CD20 (VENcombo) in R/R CLL.
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features in VENmono-treated patients,16-18 the observed survival
outcomes were similar in the VENmono and VENcombo groups.
Although we collected detailed information on VEN dose reductions
and interruptions, we did not have detailed data on the administra-
tion schedule and rationale for the anti-CD20 antibody component
of the regimen. Thus, we cannot confirm adherence to published
combination fixed duration approaches nor have available data on
prognostic factors for all patients. Importantly, however, these
cohorts do reflect real-world practice across a large number of
centers, which addresses an important evidence gap because
clinical trial participants are not often representative of routine
clinical practice. Regarding response data and survival outcomes,
the inclusion of clinical trial participants could potentially introduce
bias if imbalanced across comparator groups; however, the propor-
tion of trial participants was similar and were included to capture
the entire VEN experience across centers. Although follow-up and
response assessments were not standardized due to study design,
times to best response were comparable, suggesting these patients
were assessed similarly. In addition, we did not confirm all patients
with reported CRs had confirmatory bone marrow and computed
tomography assessments. With regard to AEs, the retrospective
design may make it difficult to capture all events (particularly grade
1 to 2) and therefore underestimates the true VEN toxicity profile. To
address this issue, we limited the number of AEs to those of highest
clinical importance and note that our AE data are comparable to the
incidence of these events reported in clinical trials. Finally, although
a few patients treated with VEN plus obinutuzumab were included,
we note this comparison did not include enough patients to make
conclusions about specific anti-CD20 antibodies or use of VEN
plus obinutuzumab in the front-line setting.
Of late, clinical trials in CLL have focused primarily on biologic
doublets and triplets.5,19-26 As multiple studies have demonstrated
superior outcomes with the addition of CD20 antibodies to chemo-
therapy in both CLL and B-cell lymphomas, one would assume the
same for small-molecule inhibitors. To date, this finding is not
observed with ibrutinib in randomized comparisons. Burger et al
demonstrated the lack of improved survival outcomes with the
addition of R to ibrutinib in a 2-arm study of treatment-naive
and relapsed CLL.6,9 These results were confirmed in the front-
line ALLIANCE study comparing ibrutinib, R plus ibrutinib, and
bendamustine plus R, which demonstrated a nearly identical 2-year
PFS in the 2 ibrutinib-containing arms.7,8 Prior to reporting these
randomized data, single-arm studies of ibrutinib plus anti CD20
strongly supported the idea that anti-CD20 therapy would improve
depth of response and survival outcomes, particularly in high-risk
patients.9 Although we note different mechanisms of action be-
tween ibrutinib and VEN, these data highlight that hypotheses
generated from nonrandomized phase 2 data are not always
confirmed in randomized studies.10,27
Unlike patients included in the MURANO trial (BR vs VR in R/R
CLL) with 1 median prior therapy, essentially ibrutinib naive (2.6%
B-cell receptor inhibitor exposure) and 27% del17p, our cohort
was more heavily pretreated (median 3 prior therapies; 78%
previously treated with ibrutinib) and higher risk (43% del17p).1,28
We hypothesize that our cohort, which may reflect current VEN use
in clinical practice, likely contains a higher proportion of anti-CD20
refractory patients. This may explain the observed lack of benefit
for the anti-CD20–containing combination over VENmono. This
analysis provides a hypothesis that adding anti-CD20 antibodies
to VEN in heavily pretreated patients may not improve clinically
relevant outcomes.
These findings need to be confirmed and validated in future
randomized studies examining (1) VEN monotherapy vs combi-
nations and (2) treat to progression vs fixed duration/retreatment
schedules. Unfortunately, we were not able to identify an ongoing
or planned clinical study that compares a VEN-based combina-
tion to VEN monotherapy. Given the increasing financial burden
of novel therapies, the lack of data on how to sequence after
novel-novel combinations fail, and the potential for increased
toxicity, our results demonstrate that it is imperative to include
monotherapy control arms as we continue to investigate the
incremental clinical benefit of novel agent combinations for
patients with CLL.29
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